Scinai Immunotherapeutics Ltd. (SCNI) stock forecast & analysis
1.56
NasdaqCM · USD
Down: -0.06, -3.7%
1.53Down: -0.03, -1.9%
1 analysis
- Open
- 1.60
- Previous close
- 1.62
- Day range
- 1.50 – 1.77
- 52-week range
- 1.43 – 16.30
- Volume (shares)
- 211.80K
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 677.58K
- P/E ratio
- 0.06
- Dividend yield
- Not available
- Beta
- 2.08
- Market cap
- 1.06M
Market Scanner’s AI analysis of Scinai Immunotherapeutics Ltd. (SCNI), updated September 2026: SCNI's strategic pivot to NanoAb and CDMO business contrasted with significant financial losses and mixed technical indicators.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Scinai Immunotherapeutics Ltd. (SCNI) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
SCNI's strategic pivot to NanoAb and CDMO business contrasted with significant financial losses and mixed technical indicators.
Recent analyses for SCNI covered a strategic refocusing towards its NanoAb platform and CDMO business, including new leadership appointments in supply chain. This strategic shift is occurring alongside significant financial challenges, including substantial net losses and negative gross profit, despite strong year-over-year revenue growth. Technical indicators present a mixed picture, with a recent price surge but the stock trading below key moving averages.
SCNI news & sentiment
News coverage highlighted Scinai's strategic pivot towards its NanoAb platform and CDMO business, with reports noting increased CDMO momentum and leadership appointments. Social media discussion was not covered in the provided notes.
SCNI technical picture
SCNI's price action showed a recent surge, but it remains below its 50-day and 200-day moving averages. Momentum indicators were mixed, with short-term positive readings but neutral RSI and strong buying pressure from the MFI. MACD readings were also noted.
Fundamentals
SCNI demonstrated significant year-over-year quarterly revenue growth, but also experienced substantial losses with negative profit and operating margins. The company reported net losses in most periods, though one prior quarter showed a net income. Liquidity ratios indicated a current and quick ratio above 1.
Factors discussed — upside
- Year-over-year quarterly revenue growth of 146%
- Recent 7-day price change of +31.2%
- Strong buying pressure indicated by MFI of 94.72
- Reported increase in CDMO momentum in H1 2026
- Net income of 3,577,000 in the quarter ending March 31, 2026
Factors discussed — risks
- Current price below 50-day and 200-day SMAs
- Significant net losses reported, with a net loss of -2,003,000 for the quarter ending June 30, 2026
- Negative Profit Margin of -174.8% and Operating Margin TTM of -466.5%
- Negative Gross Profit TTM of -3,752,000
- 30-day and 91-day price changes indicate potential lack of sustained upward momentum
- Strategic refocus
- Financial performance
- Technical indicators
- CDMO business
Summary updated .
SCNI technical indicators
Common technical indicators for SCNI, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 2.39 | Price below |
| 10-day exponential moving average | 1.79 | Price below |
| Relative strength index (14-day) | 38.07 | Neutral |
| MACD line (12/26/9) | -0.2745 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 1.07 – 3.31 | Price inside the bands |
Analyses
Recent SCNI.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Scinai Immunotherapeutics Ltd.?
- The bull case for SCNI centers on strong top-line expansion, evidenced by significant year-over-year revenue growth and a recent surge in stock price. The company has also reported a substantial net income in a prior quarter and shows strong buying pressure according to the Money Flow Index.
- What are the risks for Scinai Immunotherapeutics Ltd.?
- The bear case for SCNI highlights considerable financial headwinds, including substantial net losses, negative profit and operating margins, and a negative gross profit. The stock is trading below key moving averages, and recent price changes suggest that the upward momentum may not be sustained in the medium to long term.
- Is Scinai Immunotherapeutics Ltd. bullish or bearish?
- Recent AI analyses of Scinai Immunotherapeutics Ltd. examined factors on both sides. Discussed upside: The bull case for SCNI centers on strong top-line expansion, evidenced by significant year-over-year revenue growth and a recent surge in stock price. The company has also reported a substantial net income in a prior quarter and shows strong buying pressure according to the Money Flow Index. Discussed risks: The bear case for SCNI highlights considerable financial headwinds, including substantial net losses, negative profit and operating margins, and a negative gross profit. The stock is trading below key moving averages, and recent price changes suggest that the upward momentum may not be sustained in the medium to long term. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Scinai Immunotherapeutics Ltd.?
- News coverage highlighted Scinai's strategic pivot towards its NanoAb platform and CDMO business, with reports noting increased CDMO momentum and leadership appointments. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse Scinai Immunotherapeutics Ltd.?
- Every analysis of Scinai Immunotherapeutics Ltd. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh SCNI.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every SCNI.US report already in the library